Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC

Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study published in The New England Journal of Medicine.“Advanced HCC carries a poor prognosis, and [although] things have improved in the past few years with several new drug approvals, we have not had any improvement in OS in the first-line setting for over 12 years,” Richard S. Finn, MD, professor of medicine in the department of medicine, division of hematology/oncology, atRead More